Affimed N.V. (LON:0HL9)

Market Cap	1.23K -100.0%
Revenue (ttm)	4.69M -72.9%
Net Income	-58.23M
EPS	-3.78
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5
Average Volume	678
Open	0.0000
Previous Close	0.0000
Day's Range	0.0000 - 0.0000
52-Week Range	0.0000 - 1.1200
Beta	1.46
RSI	39.56
Earnings Date	Mar 27, 2026

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatme...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2000
• Employees: 76
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HL9

Financial Performance

In 2023, Affimed's revenue was 13.91 million, a decrease of -67.39% compared to the previous year's 42.67 million. Losses were -105.94 million, 23.2% more than in 2022.

Financial numbers in EUR